Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity von Ryn, Joanne van, Stangier, Joachim, Haertter, Sebastian, Liesenfeld, Karl-Heinz, Wienen, Wolfgang, Feuring, Martin, Clemens, Andreas

Volltext

Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab von Honickel, Markus, Treutler, Stefanie, Ryn, Joanne van, Tillmann, Sabine, Rossaint, Rolf, Grottke, Oliver

Volltext

Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran von van Ryn, Joanne, PhD, Baruch, Lawrence, MD, Clemens, Andreas, MD

Volltext

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran von Glund, Stephan, Moschetti, Viktoria, Norris, Stephen, Stangier, Joachim, Schmohl, Michael, Ryn, Joanne van, Lang, Benjamin, Ramael, Steven, Reilly, Paul

Volltext

Effects of Dabigatran in Mouse Models of Aging and Cerebral Amyloid Angiopathy von Michael, Neethu, Grigoryan, Mher Mahoney, Kilday, Kelley, Sumbria, Rachita K, Vasilevko, Vitaly, van Ryn, Joanne, Cribbs, David H, Paganini-Hill, Annlia, Fisher, Mark J

Volltext

A specific antidote for dabigatran: functional and structural characterization von Schiele, Felix, van Ryn, Joanne, Canada, Keith, Newsome, Corey, Sepulveda, Eliud, Park, John, Nar, Herbert, Litzenburger, Tobias

Volltext

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis von Pollack, Charles V, Reilly, Paul A, van Ryn, Joanne, Eikelboom, John W, Glund, Stephan, Bernstein, Richard A, Dubiel, Robert, Huisman, Menno V, Hylek, Elaine M, Kam, Chak-Wah, Kamphuisen, Pieter W, Kreuzer, Jörg, Levy, Jerrold H, Royle, Gordon, Sellke, Frank W, Stangier, Joachim, Steiner, Thorsten, Verhamme, Peter, Wang, Bushi, Young, Laura, Weitz, Jeffrey I

Volltext

Use of dabigatran etexilate to reduce breast cancer progression von DeFeo, Karen, Hayes, Candace, Chernick, Michael, Van Ryn, Joanne, Gilmour, Susan K.

Volltext

Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-b... von Glund, Stephan, Dr, Stangier, Joachim, PhD, Schmohl, Michael, PhD, Gansser, Dietmar, PhD, Norris, Stephen, PhD, van Ryn, Joanne, PhD, Lang, Benjamin, Dipl Math oec, Ramael, Steven, MD, Moschetti, Viktoria, MD, Gruenenfelder, Fredrik, DVM, Reilly, Paul, PhD, Kreuzer, Jörg, Prof

Volltext

Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin von Eisert, Wolfgang G, Hauel, Norbert, Stangier, Joachim, Wienen, Wolfgang, Clemens, Andreas, van Ryn, Joanne

Volltext

Thrombin promotes diet-induced obesity through fibrin-driven inflammation von Kopec, Anna K, Abrahams, Sara R, Thornton, Sherry, Palumbo, Joseph S, Mullins, Eric S, Divanovic, Senad, Weiler, Hartmut, Owens, 3rd, A Phillip, Mackman, Nigel, Goss, Ashley, van Ryn, Joanne, Luyendyk, James P, Flick, Matthew J

Volltext

Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment von Eikelboom, John W., van Ryn, Joanne, Reilly, Paul, Hylek, Elaine M., Elsaesser, Amelie, Glund, Stephan, Pollack, Charles V., Weitz, Jeffrey I.

Volltext

Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental... von Grottke, Oliver, van Ryn, Joanne, Spronk, Henri M H, Rossaint, Rolf

Volltext

Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease von Sparkenbaugh, Erica M., Chantrathammachart, Pichika, Mickelson, Jacqueline, van Ryn, Joanne, Hebbel, Robert P., Monroe, Dougald M., Mackman, Nigel, Key, Nigel S., Pawlinski, Rafal

Volltext

Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran von Na, Shin-Young, Mracsko, Eva, van Ryn, Joanne, Veltkamp, Roland

Volltext

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate von Gorp, Rick H., Dijkgraaf, Ingrid, Bröker, Vanessa, Bauwens, Matthias, Leenders, Peter, Jennen, Danyel, Dweck, Marc R., Bucerius, Jan, Briedé, Jacco J., Ryn, Joanne, Brandenburg, Vincent, Mottaghy, Felix, Spronk, Henri M. H., Reutelingsperger, Chris P., Schurgers, Leon J.

Volltext

Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation von Grottke, Oliver, MD, PhD, Honickel, Markus, MD, van Ryn, Joanne, PhD, ten Cate, Hugo, MD, PhD, Rossaint, Rolf, MD, Spronk, Henri M., PhD

Volltext

Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice von Preusch, Michael R, Ieronimakis, Nicholas, Wijelath, Errol S, Cabbage, Sara, Ricks, Jerry, Bea, Florian, Reyes, Morayma, van Ryn, Joanne, Rosenfeld, Michael E

Volltext

Comments on—Switching from vitamin K antagonist to dabigatran in atrial fibrillation: differences according to dose von Heinrich-Nols, Jutta, van Ryn, Joanne

Volltext

Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model von Honickel, Markus, Maron, Benjamin, Ryn, Joanne van, Braunschweig, Till, Cate, Hugo ten, Spronk, Henri M. H., Rossaint, Rolf, Grottke, Oliver

Volltext